Category: Home

CLA and vitamin D

CLA and vitamin D

The method of any CLA and vitamin D of claimsvitamun the dose vitqmin CLA and vitamin D citamin two or more unit Ribose metabolism pathway forms. Therefore, proper identification, specification, and use of combination compositions can allow for significant improvements in the reduction and prevention of age-related loss of muscle mass and function. Another study demonstrated the short term use of high concentrated omega-3 fatty acids 4g for 2 months stimulates muscle synthesis in an elderly population. Shop By Category See more Close menu. CLA and vitamin D

Video

Stop Wasting Your Money on These 7 USELESS Supplements! - Dr. Steven Gundry

Vitamjn Use Cross Minus. Subscribe and you'll get first snd CLA and vitamin D new bitamin, giveaways, and promotions. BCAAs and anti-aging store requires javascript to be enabled vittamin some features to work correctly.

Sale ends February 18th. Shop By Category See more Vita,in menu. Seriously Delicious Omega-3 Supplements See more Close menu. Barlean's Favorites See more Close menu. About Us. CLA and vitamin D 0 Cart. Load more. View in your space. Fresh Apple CLA Seriously Delicious Specialties.

Derived from natural safflower oil, a plant-based source of linoleic acid, Tonalin® CLA is clinically proven to reduce body fat while maintaining lean body mass, and preventing fat regain.

Delicious straight off the spoon or in yogurt, oatmeal or smoothies. Keep out of reach of children and never give to pets. Refrigerate after opening. Add to cart Added Sold out Unavailable Add to cart.

Click here to be notified by email when Fresh Apple CLA becomes available. You may also like. Join our Mailing List Subscribe and you'll get first dibs on new products, giveaways, and promotions.

SIGN UP Chevron. Barleans Range.

: CLA and vitamin D

CLA Supplement - Naturally Derived Safflower CLA | Barlean's – Barlean's Organic Oils, LLC CLA and vitamin D, in the form of citrulline malate, is amd as a Heart health monitoring athletic vutamin supplement was vitamih CLA and vitamin D to promote aerobic energy adn and to increase athletic performance and decreasing muscle soreness. The method of any one of claimswherein the CLA is administered in an amount from about 2. Vitamin D supplementation interacts with muscle via the receptor VDR, which hypothesized to affect downstream regulation of insulin-like growth factor signaling pathway. Randomized Controlled Trial to Evaluate the Independent and Combined Effects of CLA and. On Sale. In some embodiments, the dose is administered in two or more unit dosage forms.
Latest news

Seriously Delicious Omega-3 Supplements See more Close menu. Barlean's Favorites See more Close menu. About Us. Search 0 Cart. Load more.

View in your space. Fresh Apple CLA Seriously Delicious Specialties. Derived from natural safflower oil, a plant-based source of linoleic acid, Tonalin® CLA is clinically proven to reduce body fat while maintaining lean body mass, and preventing fat regain.

Delicious straight off the spoon or in yogurt, oatmeal or smoothies. Keep out of reach of children and never give to pets. Refrigerate after opening. Leucine may be used as a free amino acid, or in a bound form, such as a dipeptide, an oligopeptide, a polypeptide or a protein.

Common protein sources of leucine are dairy proteins such as whey, casein, micellar casein, caseinate, and glycomacroprotein GMP , and vegetable proteins such as wheat, rice, pea, lupine and soy proteins. Said sources of protein may provide intact proteins, hydrolysates or mixtures thereof, hereafter further called proteinaceous matter.

Leucine is known as a potent activator of muscle protein synthesis. Citrulline is an a- amino acid. Citrulline, in the form of citrulline malate, is sold as a performance-enhancing athletic dietary supplement was been suggested to promote aerobic energy production and to increase athletic performance and decreasing muscle soreness.

In the human body, citrulline is produced from ornithine and carbamoyl phosphate in one of the central reactions in the urea cycle.

It is also produced from arginine in the body as a by-product of the reaction catalyzed by NOS family. Citrulline is also capable of promoting muscle protein synthesis and has been described in human and animal studies. Creatine is a nitrogenous organic acid that is produced in vertebrates, in particular the human body from L-arginine, glycine, and L- methionine and helps to supply energy to muscles.

In some embodiments, such daily dosage is administered as a single serving. In the context of this application, with "free form" is meant a peptide comprising 1 to 5 amino acids, preferably 1 to 3 amino acids, more preferably 1 amino acid.

Preferably, leucine is a free amino acid, either as a base, a salt or a chelate. In some embodiments, citrulline is provided in a daily dosage of 0. In some embodiments, creatine is provided in a daily dosage of 0.

In some embodiments, any combination of leucine, citrulline, and creatine is provided in a daily dosage of 0. Any combination is a combination selected from the group of leucine and citrulline; leucine and creatine; citrulline and creatine; and leucine, citrulline and creatine.

The whey protein may be an intact whey protein, a hydrolysed whey protein, a microparticular whey protein, a nanoparticular whey protein, a micellar whey protein, and the like. Preferably, the whey protein is an intact whey protein, i. a whey protein in its intact form, such as present in fresh milk.

whey obtained by any process for the preparation of whey known in the art, as well as whey protein fractions prepared thereof, or the proteins that constitute the bulk of the whey proteins being β-lactoglobulin, ct- lactalbumin and serum albumin, such as liquid whey, or whey in powder form, such as whey protein isolate WPI or whey protein concentrate WPC.

Whey protein concentrate is rich in whey proteins, but also contains other components such as fat, lactose and glycomacroprotein GMP , a casein-related non-globular protein. Typically, whey protein concentrate is produced by membrane filtration.

On the other hand, whey protein isolate consists primarily of whey proteins with minimal amounts of fat and lactose. Whey protein isolate usually requires a more rigorous separation process such as a combination of microfiltration and ultra-filtration or ion exchange chromatography.

In particular, sweet whey, obtained as a by-product in the manufacturing of cheese, acid whey, obtained as a by-product in the manufacturing of acid casein, native whey, obtained by milk microfiltration or rennet whey, obtained as a byproduct in the manufacturing of rennet casein, may be used as a source of whey proteins.

In some embodiments, the at least one other ingredient is provided in amounts sufficient to elicit noticeable effects which can be measured as described herein. The compositions can be administered to a subject orally or by any other methods.

Methods of oral administration include, in some embodiments, administering the composition as a liquid, a solid, or a semisolid that can be taken in the form of a dietary supplement or a foodstuff. The CLA and vitamin D may be formulated together with suitable carriers such as starch, sucrose or lactose in tablets, pills, dragees, capsules, solutions, liquids, slurries, suspensions and emulsions.

The vitamin D and CLA may be administered separately or together, provided that the total amount of CLA and vitamin D is an effective amount in combination per day to have a substantial impact on the rate of muscle protein synthesis.

For example, the food composition can be, or comprise, a nutritional complete formula, a dairy product, a chilled or shelf stable beverage, a powdered beverage, a mineral or purified water, a liquid drink, a soup, a dietary supplement, a meal replacement, a nutritional bar, a confectionery, a milk, a fermented milk product, a yoghurt, a milk based powder, an enteral nutrition product, an infant formula, an infant nutritional product, a cereal product or a fermented cereal-based product, an ice cream, a chocolate, coffee, a culinary product such as mayonnaise, tomato puree, salad dressings, a pet food, or any combination thereof.

They are formulated by means of the usual methods for producing sugar-coated tablets, pills, pastes, gums, gelatin capsules, gels, emulsions, tablets, capsules or drinkable solutions or emulsions, which can then be taken directly with water or by any other known means.

This supplement may also include a sweetener, a stabilizer, an additive, a flavoring or a colorant. A supplement for cosmetic purpose can additionally comprises a compound active with respect to the skin.

Methods for preparing them are common knowledge. The composition may also contain synthetic or natural bioactive ingredients such as amino acids, fatty acids, vitamins, minerals, carotenoids, polyphenols, etc.

According to some embodiments, the composition disclosed herein can be used cosmetically. In therapeutic applications, compositions are administered to a patient already suffering from a disease, as described herein under, in an amount sufficient to cure or at least partially arrest the symptoms of the disease and its complications.

An amount adequate to accomplish this is defined as "a therapeutically effective dose". Amounts effective for this will depend on the severity of the disease and the weight and general state of the patient. In prophylactic applications, compositions disclosed herein are administered to a patient susceptible to or otherwise at risk of a particular disease.

Such an amount is defined to be "a prophylactic effective dose". In this use, the precise amounts again depend on the patient's state of health and weight. The desired formulation can be made using a variety of excipients including, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, cellulose, magnesium carbonate.

This composition may be a tablet, a capsule, a pill, a solution, a suspension, a syrup, a dried oral supplement, a wet oral supplement. For administration via intravenous infusion, the composition is preferably in a water-soluble non-toxic form.

Intravenous administration is particularly suitable for hospitalized patients that are undergoing intravenous IV therapy. For example, the composition can be dissolved in an IV solution e. The amounts of the composition to be administered intravenously can be similar to levels used in oral administration.

Intravenous infusion may be more controlled and accurate than oral administration. In some embodiments, the combination of CLA and vitamin D are formulated for administration with a pharmaceutically acceptable carrier or diluent.

The exact nature of the formulation will depend upon several factors including the desired route of administration. Typically, combination of CLA and vitamin D are formulated for oral, intravenous, intragastric, intravascular or intraperitoneal administration.

Standard pharmaceutical formulation techniques may be used, such as those disclosed in Remington's The Science and Practice of Pharmacy, 21st Ed. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic compositions is contemplated.

In addition, various adjuvants such as are commonly used in the art may be included. Considerations for the inclusion of various components in pharmaceutical compositions are described, e.

As used herein, a "unit dosage form" is a composition that is suitable for administration to an animal, preferably mammal subject, in a single dose, according to good medical practice.

The preparation of a single or unit dosage form however, does not imply that the dosage form is administered once per day or once per course of therapy. Such dosage forms are contemplated to be administered once, twice, thrice or more per day and may be administered as infusion over a period of time e.

The skilled artisan will recognize that the formulation does not specifically contemplate the entire course of therapy and such decisions are left for those skilled in the art of treatment rather than formulation.

The skilled artisan will appreciate that oral and nasal compositions include compositions that are administered by inhalation, and made using available methodologies. Depending upon the particular route of administration desired, a variety of pharmaceutically-acceptable carriers well-known in the art may be used.

Pharmaceutically-acceptable carriers include, for example, solid or liquid fillers, diluents, hydrotropies, surface-active agents, and encapsulating substances. Optional pharmaceutically-active materials may be included, which do not substantially interfere with the inhibitory activity of the composition.

The amount of carrier employed in conjunction with the composition is sufficient to provide a practical quantity of material for administration per unit dose of the composition.

Techniques and compositions for making dosage forms useful in the methods described herein are described in the following references, all incorporated by reference herein: Modern Pharmaceutics, 4th Ed. Tablets can be compressed, tablet triturates, enteric-coated, sugar-coated, film-coated, or multiple-compressed, containing suitable binders, lubricants, diluents, disintegrating agents, coloring agents, flavoring agents, flow-inducing agents, and melting agents.

Tablets typically comprise conventional pharmaceutically-compatible adjuvants as inert diluents, such as calcium carbonate, sodium carbonate, mannitol, lactose and cellulose; binders such as starch, gelatin and sucrose; disintegrants such as starch, alginic acid and croscarmelose; lubricants such as magnesium stearate, stearic acid and talc.

Glidants such as silicon dioxide can be used to improve flow characteristics of the powder mixture. Sweeteners and flavoring agents, such as aspartame, saccharin, menthol, peppermint, and fruit flavors, are useful adjuvants for chewable tablets.

Capsules typically comprise one or more solid diluents disclosed above. The selection of carrier components depends on secondary considerations like taste, cost, and shelf stability, which are not critical, and can be readily made by a person skilled in the art.

The pharmaceutically-acceptable carriers suitable for preparation of such compositions are well known in the art. Typical components of carriers for syrups, elixirs, emulsions and suspensions include ethanol, glycerol, propylene glycol, polyethylene glycol, liquid sucrose, sorbitol and water.

For a suspension, typical suspending agents include sodium carboxymethyl cellulose, AVICEL RC, tragacanth and sodium alginate; typical wetting agents include lecithin and polysorbate 80; and typical preservatives include methyl paraben and sodium benzoate. Peroral liquid compositions may also contain one or more components such as sweeteners, flavoring agents and colorants disclosed above.

Such compositions typically comprise one or more of soluble filler substances such as sucrose, sorbitol and mannitol; and binders such as acacia, microcrystalline cellulose, carboxymethyl cellulose and hydroxypropyl methyl cellulose. Glidants, lubricants, sweeteners, colorants, antioxidants and flavoring agents disclosed above may also be included.

Topical formulations may generally be comprised of a pharmaceutical carrier, co-solvent, emulsifier, penetration enhancer, preservative system, and emollient.

Suitable excipients may be included to achieve the desired pH, including but not limited to NaOH, sodium carbonate, sodium acetate, HC1, and citric acid. In various embodiments, the pH of the final composition ranges from 2 to 8, or preferably from 4 to 7. Antioxidant excipients may include sodium bisulfite, acetone sodium bisulfite, sodium formaldehyde, sulfoxylate, thiourea, and EDTA.

Other non-limiting examples of suitable excipients found in the final intravenous composition may include sodium or potassium phosphates, citric acid, tartaric acid, gelatin, and carbohydrates such as dextrose, mannitol, and dextran.

Further acceptable excipients are described in Powell, et al, Compendium of Excipients for Parenteral Formulations, PDA J Pharm Sci and Tech , 52 and Nema et al. Antimicrobial agents may also be included to achieve a bacteriostatic or fungistatic solution, including but not limited to phenylmercuric nitrate, thimerosal, benzethonium chloride, benzalkonium chloride, phenol, cresol, and chlorobutanol.

In some embodiments, the compositions are provided in solution ready to administer parenterally. In some embodiments, the compositions are provided in a solution that is further diluted prior to administration. In embodiments that include administering the compositions described herein and another agent s for example, agent A, agent B, or a combination thereof , the combination may be provided to caregivers as a mixture, or the caregivers may mix the two agents prior to administration, or the two agents may be administered separately.

Therefore, it is desirable to package CLA and vitamin D with suitable antioxidants such as lecithin, tocopherols, ascorbate, ascorbyl palmitate or spice extracts such as rosemary extract.

An additional ingredient may serve one or more functions. In some embodiments, an additional ingredient accounts for about, less than about, or more than about 0. Non-limiting examples of additional ingredients include sweeteners, bulking agents, stabilizers, acidulants, preservatives, binders, lubricants, disintegrants, fillers, solubilizers, coloring agents such as fruit juice and vegetable juice , and other additives and excipients known in the art.

In some embodiments, a combination composition comprises one or more e. In some embodiments, the sweetener is a polyol additive, such as a sugar alcohol, erythritol, maltitol, mannitol, sorbitol, lactitol, xylitol, inositol, isomalt, propylene glycol, glycerol glycerine , threitol, galactitol, palatinose, reduced isomalto-oligosaccharides, reduced xylo-oligosaccharides, reduced gentio- oligosaccharides, reduced maltose syrup, or reduced glucose syrup.

Non-limiting examples of bulking agents include guar gum, locust bean gum, cassia gum, pectin from botanical sources, high molecular weight carboxymethylcellulose, carrageenan, alginate, and xanthane. In some embodiments, one or more bulking agents may be added to enhance the viscosity of a liquid formulation.

Non-limiting examples of stabilizers include pectin, polysaccharide hydrolysates comprising dextrin, agar, can- ageenan, tamarind seed polysaccharides, angelica gum, karaya gum, xanthan gum, sodium alginate, tragacanth gum, guar gum, locust bean gum, pullulan, gellan gum, gum arabic, carboxymethylcellulose, and propylene glycol alginate ester.

In some embodiments, one or more stabilizers are added to the combination composition to enhance the shelf-life of the combination composition.

In general, shelf-life refers to the amount of time the container and composition therein can be held at ambient conditions approximately room temperature, e. about ° C. In some embodiments, the combination composition has a shelf life of about, less than about, or more than about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1, 12, 14, 30, 60, 90, or more days; or about, less than about, or more than about 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or more months or years.

In some embodiments, the combination composition remains non-perishable for a period of time after opening a container containing the composition. In general, perishability refers to degradation to an extent that the composition cannot be used in the manner and purpose for which it was designed.

In some embodiments, the combination composition remains non-perishable for about, less than about, or more than about 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12, 18, 24, 30, 36, 48, 60, 72, 90, or more hours or days after opening; or about, less than about, or more than about 1, 2, 3, 4, 5, 6, 8, 10, 11, 12, or more months or years after opening.

In some embodiments, the combination composition remains nonperishable for a period of time at room temperature e.

In some embodiments, the combination composition remains non-perishable for a period of time upon refrigeration, such as storage below about 20° C, 15° C, 10° C, 5° C, 4° C, 3° C, 2° C, 1° C, 0° C, -1° C, -2° C, -3° C, -4° C, -5° C, ° C, ° C, or lower.

Non-limiting examples of acidulants include C2-C30 carboxylic acids, substituted hydroxyl C1-C30 carboxylic acids, benzoic acid, substituted benzoic acids e.

Non-limiting examples of preservatives include sorbic acid, benzoic acid, and salts thereof, including but not limited to calcium sorbate, sodium sorbate, potassium sorbate, calcium benzoate, sodium benzoate, potassium benzoate, and mixtures thereof.

For example, the snack bar can be a chocolate bar, a granola bar, or a trail mix bar. In some embodiments, the present dietary supplement or food compositions are formulated to have suitable and desirable taste, texture, and viscosity for consumption. Any suitable food carrier can be used in the present food compositions.

Food carriers of the compositions described herein include practically any food product. Examples of such food carriers include, but are not limited to food bars granola bars, protein bars, candy bars, etc. In some embodiments, food carriers employed herein can mask the undesirable taste e.

Where desired, the food composition presented herein exhibit more desirable textures and aromas than that of any of the components described herein. For example, liquid food carriers can be used to obtain the present food compositions in the form of beverages, such as supplemented juices, coffees, teas, shakes e.

In some embodiments, solid food carriers can be used to obtain the present food compositions in the form of meal replacements, such as supplemented snack bars, pasta, breads, and the like. In some embodiments, semi-solid food carriers can be used to obtain the present food compositions in the form of gums, chewy candies or snacks, and the like.

The term "pharmaceutically acceptable salt" refers to salts that retain the biological effectiveness and properties of a compound and, which are not biologically or otherwise undesirable for use in a pharmaceutical.

Pharmaceutically acceptable acid addition salts can be formed with inorganic acids and organic acids. Inorganic acids from which salts can be derived include, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like.

Organic acids from which salts can be derived include, for example, acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, and the like.

Pharmaceutically acceptable salts can also be formed using inorganic and organic bases. Inorganic bases from which salts can be derived include, for example, bases that contain sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum, and the like; particularly preferred are the ammonium, potassium, sodium, calcium and magnesium salts.

In some embodiments, treatment of the compounds disclosed herein with an inorganic base results in loss of a labile hydrogen from the compound to afford the salt form including an inorganic cation such as Li , Na , K , Mg and Ca and the like.

Organic bases from which salts can be derived include, for example, primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, basic ion exchange resins, and the like, specifically such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, and ethanolamine.

Such information may be based on the results of various studies, for example, studies using experimental animals involving in vivo models and studies based on human clinical trials. A kit may comprise one or more unit doses described herein. In some embodiments, a kit comprises about, less than about, or more than about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 30, 31, 60, 90, , , , , or more unit doses.

Instructions for use can comprise dosing instructions, such as instructions to take 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more unit doses 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more times per day.

For example, a kit may comprise a unit dose supplied as a tablet, with each tablet package separately, multiples of tablets packaged separately according to the number of unit doses per administration e.

pairs of tablets , or all tablets packaged together e. in a bottle. As a further example, a kit may comprise a unit dose supplied as a bottled drink, the kit comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 24, 28, 36, 48, 72, or more bottles.

In some embodiments, the CLA and vitamin D are provided as separate compositions in separate containers within the kit. In some embodiments, the CLA and vitamin D are provided as a single composition within a container in the kit.

Suitable packaging and additional articles for use e. Kits can also, in some embodiments, be marketed directly to the consumer. The unit dosages can be any unit dosage described herein. The kit can comprise instructions directing the administration of the multi-day supply of unit dosages over a period of multiple days.

The multi-day supply can be a one-month supply, a day supply, or a multi-week supply. The multi-day supply can be a day, day, 3 -month or 6-month supply. The kit can include packaged daily unit dosages, such as packages of 1, 2, 3, 4, or 5 unit dosages.

The kit can be packaged with, for example, other dietary supplements, vitamins, and meal replacement bars, mixes, and beverages. Randomized Controlled Trial to Evaluate the Independent and Combined Effects of CLA and.

Vitamin D on the Rate of Muscle Protein Synthesis in Older Adults. Forty 40 year old men and women "Subjects" are randomized to receive: i placebo 4, mg corn oil per day , ii CLA 4, mg Tonalin FFA 80 per day , iii vitamin D 3 2, IU per day , or iv CLA 4, mg Tonalin FFA 80 per day plus vitamin D 3 2, IU per day for 8 weeks.

Study supplements are provided in finished bottles according to labeling guidelines. The study is conducted by a protocol described in Smith et al, Am. It is expected that both CLA and vitamin D will stimulate muscle protein anabolism and the effect of CLA plus vitamin D will be greater than the effect of either intervention alone.

Written informed consent is obtained from all subjects before they are enrolled in the study. Within this cohort, subjects who: i use medications that are incompatible with the study procedures e. At h, they consume a standardized meal and then fast except for water and rest in bed until the completion of the study outlined in Figure 1 the next day.

At h, constant infusions of [ring- 2 H5]phenylalanine priming dose: 7. The infusion rate of [ring- 2 H5]phenylalanine is increased to 0. Data average values collected at , , , and min basal period and , , , and min clamp are used to calculate forearm amino acid net balance, protein breakdown and protein synthesis.

Data obtained from the remaining samples are used to confirm isotopic and metabolic steady state. Subcutaneous adipose tissue biopsies from the periumbilical region are obtained during local anesthesia immediately after the first and third muscle biospies at 60 and min. Plasma glucose concentration is determined on an automated glucose analyzer Yellow Spring Instruments Co, Yellow Springs, OH.

Plasma insulin concentration is measured by using a commercially available ELISA kit Diagnostic Systems Labs, Webster, TX.

The phenylalanine tracer to tracee ratio TTR and concentration in blood and the muscle free and protein-bound phenylalanine TTR will be determined by GC-MS MSD System, Hewlett-Packard by using enrichment standards.

Protein bands are visualized and quantified by densitometry ensuring no pixel saturation. is used to evaluate the muscle mRNA expression of peroxisome proliferator-activated receptor alpha [PPARA] and gamma [PPARG], regulators of energy metabolism; myogenic differentiation 1 [MYOD1], a myogenic growth factor; myostatin [MSTN], a muscle growth inhibitor; follistatin [FST], which binds to and thereby inhibits myostatin; forkhead box 03 [FOX03], which induces the transcription of ubiquitin ligases; MaFbx and MuRFl, two components of the ubiquitin- proteasome pathway; Calpains and Calpastatin, a family of calcium-dependent, non- lysosomal cysteine proteases; tripeptidyl peptidase II, an enzyme responsible for the terminal steps of proteolysis; and the lysosomal peptidases, cathepsin L and cathepsin B.

TNF, IL6 , adipokines e. AdipoQ, LEP , adipogenesis e. PPARG , and mitochondrial function e. Mitochondrial function in muscle is evaluated by oxygraphy Oroboros 02k, Innsbruck, Austria.

All samples are coded in ways that do not reveal subjects' treatment status to ensure unbiased analysis. Subjects randomized to receive placebo receive 4, mg corn oil daily 2 softgels containing 1, mg corn oil each in the morning and 2 in the evening , those randomized to CLA receive 4, mg Tonalin FFA 80 daily 2 softgels containing mg CLA isomers each in the morning and 2 in the evening , those randomized to vitamin D receive 2, IU vitamin D3 daily 2 softgels containing IU vitamin D3 each in the morning and 2 in the evening , and those randomized to CLA plus vitamin D receive both 4, mg Tonalin FFA 80 and 2, IU vitamin D3 daily 2 softgels containing mg CLA isomers and iU vitamin D3 each in the morning and 2 in the evening.

CLA Tonalin 80 FFA is a dietary supplement and generally-recognized-as-safe GRAS by the Food and Drug Administration. Compliance with the treatment is assessed by pill count at the end of the study.

To avoid "tampering" with the pill count, subjects are given an to them unknown amount of pills in excess of needs at the beginning of the study and will be asked to return any remaining pills at the end of the study.

Subjects have weekly contact with a member of the study team to review body weight, food records, any signs of supplement intolerance, life events, and any medical complaints. Any indication of a potential adverse event is reviewed with the PI and study physician.

Physical activity and dietary intake during the intervention. The study coordinator instructs the subjects to do so and follow-up with them weekly to remind them and help them maintain their habitual life-style.

In addition, physical activity and dietary intake are monitored and potential changes are taken into account in the statistical analyses.

Urine and stool are collected before and at the end of the intervention to assess h urinary nitrogen excretion and fecal isovaleric acid content, two markers of dietary protein intake. To monitor physical activity, subjects wear an Acti Graph GT9X Link monitor for 7 days during the first and last week of the intervention; they also keep records of any exercise sessions in which they engage.

The user is blinded to the data collected which minimizes tampering with the monitor to achieve target readings. To account for the reasons for attrition, we plan to interview by phone subjects who decide to drop out.

Withdrawal because of treatment-related adverse events e. taste aversion, etc. is considered treatment failure; subjects are encouraged if there is no contraindication to complete all primary outcome testing procedures to avoid missing data for intention-to-treat analysis.

In all analyses, careful attention is given to the appropriateness of the statistical procedure by determining whether necessary conditions are satisfied; e. When conditions are violated, the use of data transformations intended to produce data that satisfy normality and equal variance assumptions is explored.

If an appropriate transformation cannot be found, non-parametric methods may be used as an alternative to the more standard analyses. Primary analysis is "intention-to-treat". A secondary analysis focuses on "compliant" subjects only i.

The following computations demonstrate that the study is adequately powered to detect changes in these outcomes using two-sided tests, a 0. Figure 2 depicts the expected results from the ongoing clinical trial on muscle synthetic rate in elderly subjects.

It is expected that those subjects receiving either placebo or Vitamin D alone will have a statistically significant difference in FSR under "clamp" infusion relative to the basal period, but will have not have a statistically significant difference in FSR before and after intervention indicated in Figure 2 by "a".

It is expected that those subjects receiving CLA alone will have a statistically significant difference in FSR under "clamp" infusion relative to the basal period indicated in Figure 2 by "b" and will have a statistically significant difference in FSR before and after intervention indicated in Figure 2 by "c".

It is expected that those subjects receiving CLA plus Vitamin D will have a statistically significant difference in FSR under "clamp" infusion relative to the basal period indicated in Figure 2 by "b" , will have a statistically significant difference in FSR before and after intervention indicated in Figure 2 by "c" , and will have a statistically significant difference in FSR as compared to the subjects receiving either CLA or Vitamin D alone indicated in Figure 2 by "d".

Assuming the larger SD 0. Table 1. Non-limiting exemplary composition of CLA and Vitamin D. The subject is then administered four of the softgels described in Example 2 on a daily basis with two softgels taken morning and evening daily with meals.

Method of Treating Using CLA and Vitamin D. The subject is then administered, once per day, a meal replacement bar comprising about 4 g of a CLA mixture cis-9, trans - octadecadienoic acid CLA and trans, cisoctadecadienoic acid in a 50 ratio and about IU of Vitamin D 3.

It will be appreciated by those skilled in the art that various other omissions, additions and modifications may be made to the methods and structures described above without departing from the scope of the claimed subject matter.

All such modifications and changes are intended to fall within the scope of the subject matter, as defined by the appended claims. It will be further understood by those within the art that if a specific number of an introduced claim recitation is intended, such an intent will be explicitly recited in the claim, and in the absence of such recitation no such intent is present.

For example, as an aid to understanding, the following appended claims may contain usage of the introductory phrases "at least one" and "one or more" to introduce claim recitations. However, the use of such phrases should not be construed to imply that the introduction of a claim recitation by the indefinite articles "a" or "an" limits any particular claim containing such introduced claim recitation to embodiments containing only one such recitation, even when the same claim includes the introductory phrases "one or more" or "at least one" and indefinite articles such as "a" or "an" e.

In addition, even if a specific number of an introduced claim recitation is explicitly recited, those skilled in the art will recognize that such recitation should be interpreted to mean at least the recited number e. Furthermore, in those instances where a convention analogous to "at least one of A, B, and C, etc.

In those instances where a convention analogous to "at least one of A, B, or C, etc. For example, the phrase "A or B" will be understood to include the possibilities of "A" or "B" or "A and B.

Any listed range can be easily recognized as sufficiently describing and enabling the same range being broken down into at least equal halves, thirds, quarters, fifths, tenths, etc.

As a non- limiting example, each range discussed herein can be readily broken down into a lower third, middle third and upper third, etc.

As will also be understood by one skilled in the art all language such as "up to," "at least," "greater than," "less than," and the like include the number recited and refer to ranges which can be subsequently broken down into sub-ranges as discussed above.

Finally, as will be understood by one skilled in the art, a range includes each individual member. Thus, for example, a group having articles refers to groups having 1, 2, or 3 articles. Similarly, a group having articles refers to groups having 1, 2, 3, 4, or 5 articles, and so forth.

The various aspects and embodiments disclosed herein are for purposes of illustration and are not intended to be limiting, with the true scope and spirit being indicated by the following claims. In the event that one or more of the incorporated literature and similar materials differ from or contradict this application, including but not limited to defined terms, term usage, described techniques, or the like, this application controls.

WHAT IS CLAIMED IS: 1. A composition, comprising conjugated linoleic acid CLA and Vitamin D. The composition of claim 2, wherein at least one of the one or more isomers of CLA is in triglyceride form.

The composition of claim 2, wherein at least one of the one or more isomers of CLA is in free fatty acid form. The composition of claim 2, wherein at least one of the one or more isomers of CLA is in ester form.

The composition of claim 2, wherein at least one of the one or more isomers of CLA is selected from the group comprising cis-9, cis -octadecadienoic acid, cis-9, trans- 11 -octadecadienoic acid, trans-9, cis -octadecadienoic acid, trans-9, trans octadecadienoic acid, cis, cis- octadecadienoic acid, cis, trans- octadecadienoic acid, trans- 10, cis- octadecadienoic acid, and trans- 10, trans- octadecadienoic acid.

The composition of any one of claims , wherein the CLA is a mixture of two or more different isomers of CLA. The composition of claim 7, wherein the mixture comprises cis-9, trans octadecadienoic acid CLA and trans- 10, cis- octadecadienoic acid.

The composition of claim 7, wherein the mixture comprises cis-9, trans octadecadienoic acid CLA and trans, cis- octadecadienoic acid in a ratio.

The composition of any one of claims , wherein the CLA is derived from safflower oil. The composition of any one of claims , wherein the CLA further comprises one or more tocopherols. The composition of claim 11, wherein at least one of the one or more tocopherols is selected from the group consisting of consisting of δ-tocopherol, γ-tocopherol, a-tocopherol, and combinations thereof.

The composition of any one of claims , wherein the vitamin D comprises vitamin D3, vitamin D 2 , their biologically active metabolites and precursors, or any mixtures thereof. The composition of any one of claims , comprising one or more Group A agents that diminish the inflammatory mechanism resulting in mitochondrial oxidative stress, wherein at least one of the one or more Group A agent is selected from the group comprising omega-3 fatty acids, amino acids, and vitamins.

The composition of claim 15, wherein at least one of the one or more Group A agents is aniline or Vitamin E. The composition of claim 15, wherein the omega-3 fatty acid is selected from the group consisting of alpha-linolenic acid, stearidonic acid, eicosapentanoic acid, docosahexanoic acid, and mixtures thereof.

The composition of any one of claims , comprising one or more Group B agents that positively impact the muscle stimulating mechanism. The composition of claim 18, wherein at least one of the one or more Group B agents is selected from the group consisting of a vitamin D other than vitamin D3, creatine, Vitamin D 2 , leucine, citrulline, and whey protein.

The composition of any one of claims , comprising at least one Group A agent and at least one Group B agent. The composition of any one of claims , comprising at least two Group A agents and at least two Group B agents.

The composition of any one of claims , comprising about 1 g to about 6 g of the CLA and about IU to about IU of vitamin D. The composition of any one of claims , comprising about 2 g to about 4 g of the CLA and about IU to about IU of vitamin D. The composition of any one of claims , comprising about 3 g to about 3.

The composition of any one of claims , comprising about 4 g of the CLA and about IU of vitamin D. The composition of any one of claims , comprising an effective amount of the CLA and vitamin D to treat or prevent a condition of muscle loss in a subject in need thereof. The composition of any one of claims , comprising an effective amount of the CLA and Vitamin D to reduce or prevent age-related muscle loss or function in a subject in need thereof.

The composition of any one of claims , comprising an effective amount of the CLA and Vitamin D to increase muscle protein synthesis in a subject in need thereof.

The composition of any one of claims , wherein, upon administration to a subject in need thereof, the composition has a synergistic effect on one or more of treating or preventing a condition of muscle loss, increasing muscle protein synthesis, and reducing or preventing age-related loss of muscle mass and function.

The composition of any one of claims , wherein the composition is an oral composition. The composition of claim 30, wherein the composition is a foodstuff, a food supplement, or a pharmaceutical composition.

The composition of claim 31, wherein the foodstuff comprises a nutritional complete formula, a dairy product, a chilled or shelf stable beverage, a mineral water, a liquid drink, a shot, a soup, a dietary supplement, a meal replacement bar, a nutritional bar, a confectionery product, a milk, a fermented milk product, a yogurt, a pectin chew, a gummy, a milk based powder, an enteral nutrition product, a cereal product, a fermented cereal based product, an ice cream, a chocolate, coffee, a culinary product, or an7y combination thereof.

The composition of claim 31, wherein the food supplement is in the form of capsules, gelatin capsules, soft capsules, tablets, sugar-coated tablets, powders, pills, pastes, pastilles, gums, drinkable solutions, drinkable emulsions, syrups, gels, or a combination thereof.

The composition of claim 31, wherein the pharmaceutical composition is in the form of capsules, gelatin capsules, soft capsules, tablets, chewable tablets, sugar-coated tablets, pills, pastes or pastilles, powders, softgels, chewable softgels, gums, drinkable solutions or emulsions, syrups, gels, or any combination thereof.

The composition of any one of claims , comprising one or more of binding agents, gelling agents, thickeners, colorants, taste masking agents, stabilizers, antioxidants, coatings, sweeteners, taste modifiers, and aroma chemicals.

The composition of any one of claims , wherein said composition is formulated for intravenous, intramuscular, rectal, or inhalation administration. The composition of any one of claims , comprising one or more pharmaceutically acceptable carriers, diluents or excipients.

The composition of any one of claims , wherein the composition is in a single unit dosage form. The composition of any one of claims , wherein the composition is in two or more unit dosage forms.

Use of the composition of any one of claims for treating or preventing a condition of muscle loss a subject in need thereof. The use of claim 40, wherein the use comprises increasing muscle mass, increasing muscle function, increasing the rate of muscle synthesis, or decreasing the rate of muscle breakdown in a subject in need thereof.

The use of claim 40, wherein the use comprises reducing or preventing age- related loss of muscle mass and function in a subject in need thereof. The use of claim 40, wherein the use comprises treating or preventing at least one of sarcopenia, insufficient muscle protein synthesis, muscle degradation, muscle proteolysis, muscle atrophy, muscle dystrophy, muscle catabolism, muscle wasting, loss of muscle strength, loss of physical capacity, loss of physical performance, impaired mobility, frailty, surgery, disability, risk of falling, and risk of fall-related fractures in a subject in need thereof.

The use of claim 40, wherein the use comprises treating or preventing sarcopenia in a subject in need thereof. Use of the composition of any one of claims for the manufacture of a medicament for treating or preventing a condition of muscle loss a subject in need thereof.

The use of claim 45, wherein the use comprises increasing muscle mass, increasing muscle function, increasing the rate of muscle synthesis, or decreasing the rate of muscle breakdown in a subject in need thereof. The use of claim 45, wherein the use comprises reducing or preventing age- related loss of muscle mass and function in a subject in need thereof.

The use of claim 45, wherein the use comprises increasing muscle protein synthesis in a subject in need thereof. The use of claim 45, wherein the use comprises treating or preventing at least one of sarcopenia, insufficient muscle protein synthesis, muscle degradation, muscle proteolysis, muscle atrophy, muscle dystrophy, muscle catabolism, muscle wasting, loss of muscle strength, loss of physical capacity, loss of physical performance, impaired mobility, frailty, surgery, disability, risk of falling, and risk of fall-related fractures in a subject in need thereof.

The use of claim 40 or 45, wherein the use comprises treating or preventing sarcopenia in a subject in need thereof. A method of treating or preventing a condition of muscle loss, the method comprising administering the composition of any one of claims to a subject in need thereof.

The method of claim 51, wherein the method comprises increasing muscle mass, increasing muscle function, increasing the rate of muscle synthesis, decreasing the rate of muscle breakdown, or a combination thereof in the subject in need thereof.

The method of claim 51, wherein the method comprises reducing or preventing muscle mass and function in the subject in need thereof. The method of claim 51, wherein the method comprises increasing muscle protein synthesis in the subject in need thereof.

The method of claim 51, wherein the method comprises treating or preventing at least one of sarcopenia, insufficient muscle protein synthesis, muscle degradation, muscle proteolysis, muscle atrophy, muscle dystrophy, muscle catabolism, muscle wasting, loss of muscle strength, loss of physical capacity, loss of physical performance, impaired mobility, frailty, surgery, disability, risk of falling, and risk of fall-related fractures in a subject in need thereof.

The method of claim 51, wherein the method comprises treating or preventing sarcopenia in a subject in need thereof. A method of treating or preventing a condition of muscle loss, comprising administering CLA and Vitamin D to a subject in need thereof.

The method of claim 57, wherein the CLA and Vitamin D are administered separately. The method of claim 58, wherein the CLA is administered before the Vitamin D is administered to the subject.

The method of claim 58, wherein the CLA is administered after the Vitamin D is administered to the subject. The method of claim 57, wherein the CLA and Vitamin D are administered concurrently.

The method of any one of claims , comprising increasing muscle mass, increasing muscle function, increasing the rate of muscle synthesis, or decreasing the rate of muscle breakdown in need thereof.

The method of any one of claims , wherein the method comprises reducing or preventing loss of muscle mass and function in a subject in need thereof. The method of any one of claims , wherein the method comprises increasing muscle protein synthesis in a subject in need thereof.

The method of any one of claims , comprising treating or preventing at least one of sarcopenia, insufficient muscle protein synthesis, muscle degradation, muscle proteolysis, muscle atrophy, muscle dystrophy, muscle catabolism, muscle wasting, loss of muscle strength, loss of physical capacity, loss of physical performance, impaired mobility, frailty, surgery, disability, risk of falling and risk of fall-related fractures in a subject in need thereof.

The method of any one of claims , comprising treating or preventing sarcopenia in a subject in need thereof. The method of claim 67, wherein at least one of the one or more isomers of CLA is in triglyceride form, free fatty acid form, or ester form.

The method of claim 67, wherein at least one of the one or more isomers of CLA is selected from the group comprising cis-9, cis -octadecadienoic acid, cis-9, trans- 11 -octadecadienoic acid, trans-9, cis -octadecadienoic acid, trans-9, trans octadecadienoic acid, cis, cis- octadecadienoic acid, cis, trans- octadecadienoic acid, trans- 10, cis- octadecadienoic acid, and trans- 10, trans- octadecadienoic acid.

The method of any one of claims , wherein the CLA is a mixture of two or more different isomers of CLA. The method of claim 70, wherein the mixture comprises cis-9, trans octadecadienoic acid CLA and trans- 10, cis- octadecadienoic acid.

The method of claim 70, wherein the mixture comprises cis-9, trans octadecadienoic acid CLA and trans, cis- octadecadienoic acid in a ratio. The method of any one of claims , wherein the CLA is derived from safflower oil.

The method of any one of claims , wherein the CLA further comprises one or more tocopherols. The method of claim 74, wherein the tocopherol is selected from the group consisting of consisting of δ-tocopherol, γ-tocopherol, a-tocopherol, and combinations thereof.

The method of any one of claims , wherein the vitamin D comprises vitamin D3, vitamin D 2 , their biologically active metabolites and precursors, or any mixture thereof.

The method of any one of claims , comprising administrating one or more Group A agent that diminishes the inflammatory mechanism resulting in mitochondrial oxidative stress, wherein at least one of the one or more Group A agents is selected from the group comprising omega-3 fatty acids, amino acids, and vitamins.

The method of claim 78, wherein at least one of the one or more Group A agents is aniline or vitamin E. The method of claim 78, wherein the omega-3 fatty acid is selected from the group consisting of alpha-linolenic acid, stearidonic acid, eicosapentanoic acid, docosahexanoic acid, and mixtures thereof.

The method of any one of claims , further comprising administrating one or more Group B agents that positively impacts the muscle stimulating mechanism, wherein at least one of the one or more Group B agents is selected from the group comprising another vitamin D other than Vitamin D3, citrulline, creatine, leucine, and whey protein.

The method of claim 81, wherein at least one of the one or more Group B agents is creatine, leucine, citrulline, whey protein, or vitamin D 2.

The method of any one of claims , comprising administrating at least one Group A agent and at least one Group B agent to the subject. The method of any one of claims , comprising administrating at least two Group A agents and at least two Group B agents to the subject.

The method of any one of claims , wherein CLA is administered in an amount from about 1. The method of any one of claims , wherein the CLA is administered in an amount from about 2.

The method of any one of claims , wherein the CLA is administered in an amount from about 3. The method of any one of claims , wherein the CLA is administered in an amount of about 4 g per day and the Vitamin D is administered in an amount of about IU per day.

The method of any one of claims , wherein the dose is administered in a single unit dosage form. The method of any one of claims , wherein the dose is administered in two or more unit dosage forms.

The method of any one of claims , wherein said administration of one or more of CLA, Vitamin D, Group A agent s and Group B agent s is repeated one time per day. The method of any one of claims , wherein said administration of one or more of the CLA, vitamin D, Group A agent s and Group B agent s is repeated more than one time per day.

The method of any one of claims , wherein the administration of one or more of the CLA, Vitamin D, Group A agent s and Group B agent s is oral, intravenous, intraperitoneal, intragastric, or intravascular administration. The method of any one of claims , wherein the administration of one or more of CLA, Vitamin D, Group A agent s and Group B agent s is oral administration.

The method of any one of claims , wherein the subject is an adult. The method of any one of claims , wherein the subject is a female. The method of any one of claims , wherein the subject is a middle-aged adult.

The method of any one of claims , wherein the subject is an elderly adult. The method of any one of claims , wherein the subject is human is a person of the age of 40 years or more.

The method of any one of claims , wherein the subject is human is a person of the age of 60 years or more. The method of any one of claims , wherein the subject is with an active lifestyle. The method of any one of claims , wherein the subject is with a sedentary lifestyle.

The method of any one of claims , wherein the subject has sarcopenia or is at risk of developing sarcopenia. The method of any one of claims , further comprising identifying a subject is suffering from a condition of muscle loss or is at the risk of developing a condition of muscle loss.

The method of any one of claims , further comprising determining muscle weight, muscle circumference, lean muscle, body weight, fat mass, lean mass, brain water content, locomotor activity, protein synthesis rate, or any combination thereof of the subject.

The method of any one of claims , at least one symptom of the condition of muscle loss is skeletal muscle loss, or muscle mass loss. The method of any one of claims , wherein the condition of muscle loss is caused by aging, disease, injury, inactivity, or any combination thereof.

The method of any one of claims , wherein the condition of muscle loss is selected from the group comprising sarcopenia, muscle atrophy, cachexia, muscular dystrophy, or any combination thereof.

The method of any one of claims , wherein the condition of muscle loss is sarcopenia. The method of any one of claims , wherein upon administration to a subject in need thereof, the rate of muscle protein synthesis is increased.

The method of any one of claims , wherein the increased muscle protein synthesis comprises increased muscle fractional synthesis rate FSR.

The method of any one of claims , wherein the administration of a combination of CLA and vitamin D has a synergistic effect. WOA1 true WOA1 en. Reduction and prevention of muscle loss by conjugated linoleic acid cla and vitamin d.

WOA1 en. ANONYMOUS: " CLA and Vitamin D on Protein Turnover - Full Text View - ClinicalTrials. ANSEL: " Introduction to Pharmaceutical Dosage Forms ", LIEBERMAN ET AL.

LISA CEGLIA ET AL: " Vitamin D and Its Role in Skeletal Muscle ", CURR OPIN CLIN NUTR METAB CARE, vol. NEMA ET AL. POWELL ET AL. ROSARIO BARONE ET AL: " Endurance Exercise and Conjugated Linoleic Acid CLA Supplementation Up-Regulate CYP17A1 and Stimulate Testosterone Biosynthesis ", PLOS ONE, vol.

SMITH ET AL. JPB2 en. USA1 en. USB2 en. Compositions, methods and kits for enhancing weight loss while inhibiting loss of lean body mass. JPA en. Use of proteins and essential amino acids to treat amenorrhea and related diseases.

Product reviews Vtamin method of any one of anfwherein the Boost cognitive abilities of muscle CLA and vitamin D is CLA and vitamin D. At h, constant infusions vitwmin [ring- 2 H5]phenylalanine vtamin dose: 7. CLA are vvitamin family of at least 28 isomers of linoleic acid found mostly in the meat and dairy products derived from ruminants. CLA supplementation studies in younger populations have found a reduction of muscle breakdown markers after resistance exercise. WHEN TO TAKE. Weight 0. A few of the major sources of CLA in the diet include full-fat dairy products, beef and grass-fed butter.
Conjugated Linoleic Vitqmin CLA is a natural fatty acid Multi-channel resupply solutions in safflower oil. CLA when aand as a anx of a regular CLA and vitamin D and exercise program, CLA CLA and vitamin D healthy weight management. of CLA from a four-capsule daily serving. For best results, take two softgels two times daily with meals as part of a healthy diet and lifestyle. CLA does not contain any central nervous system stimulants. SinceBronson has been providing families with the highest quality products and finest customer service available.

Author: Moogubei

1 thoughts on “CLA and vitamin D

Leave a comment

Yours email will be published. Important fields a marked *

Design by ThemesDNA.com